AstraZeneca ((AZN)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: AstraZeneca has launched a Phase I study titled ‘ARTEMIDE-subQ’ to explore the pharmacokinetics and safety of subcutaneous rilvegostomig in adults with advanced solid tumors previously treated with standard care. The study aims to find a subcutaneous dose that matches the intravenous exposure, providing a potentially more convenient treatment option for patients.
Intervention/Treatment: The study tests subcutaneous rilvegostomig, a drug intended to treat advanced solid tumors. It is compared to its intravenous counterpart to determine equivalent dosing and safety.
Study Design: This randomized, sequential study focuses on treatment, with no masking involved. Participants will receive different doses of subcutaneous rilvegostomig, alongside recombinant human hyaluronidase, to assess optimal dosing and safety.
Study Timeline: The study is set to begin on September 3, 2025, with its primary completion and estimated completion dates yet to be announced. The last update was submitted on September 5, 2025, indicating the study’s preparatory phase.
Market Implications: This study could influence AstraZeneca’s stock performance by potentially expanding treatment options for cancer patients, enhancing their market position. Investors may view this as a positive development, especially in the competitive oncology sector where innovation is key.
The study is ongoing, with further details available on the ClinicalTrials portal.